Empowering clinicians to make faster decisions with diagnostic results in real time
The CLIA-waived ID NOW™ COVID-19 2.0 assay delivers reliable molecular results in just minutes, giving you real-time access to the information you need to make actionable decisions right at the point of care.
Available under FDA Emergency Use Authorization.
Positive results as early as 6 minutes, negative results in 12 minutes
Nucleic Acid Amplification Technology (NAAT), providing molecular results in a fraction of the time it takes traditional lab tests
CLIA-waived; requires minimum training with easy on-screen steps to guide users
You can decide which tests to run based on patient presentation, circulating prevalence and seasonality of infectious diseases
| ID NOW™ System |
Code |
|---|---|
| ID NOW™ Instrument |
NAT-024 (US) |
| ID NOW™ COVID-19 2.0 24 Test Kit | 192-000 |
| ID NOW™ COVID-19 2.0 Control Kit (12 positive, 12 blank swabs) | 192-080 |
| COVID-19 Swab Transport Tube Accessory Pack, 24 Count | 190-010 |
| ID NOW™ Barcode Scanner | L22XWU1200 |
| Universal Printer | IDNOWPRINT (US) |
ID NOW™ COVID-19 2.0 has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Based on your current location, the content on this page may not be relevant for your country.
